TTRX net incomeQ3 2026-$6.23M
TTRX net income was -$6.23M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.90M a year earlier. For the full fiscal 2025 it was -$3.19M, compared with -$1.77M in fiscal 2024.
Turn Therapeutics Inc. (TTRX) financials
For the twelve months ended Sep 30, 2026, Turn Therapeutics Inc. reported -$12.77M of net income.
- Net income, TTM
- -$12.77M
- EPS, diluted, TTM
- -$0.43
- Cash
- $9.43M
- Total debt
- $6.19M
- Market cap
- $302.9M
FY2024FY2025
TTRX revenue and earnings growth
TTRX EPSQ3 2026-$0.21
TTRX diluted EPS was -$0.21 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.07 a year earlier. For the full fiscal 2025 it was -$0.12, compared with -$0.07 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Research and development | $265.6K | $246.0K |
| Selling, general and admin | $5.59M | $1.55M |
| Operating income | -$5.86M | -$1.80M |
| Net income | -$3.19M | -$1.77M |
| EPS, basic | -$0.12 | -$0.07 |
| EPS, diluted | -$0.12 | -$0.07 |
| Diluted shares | 27.7M | 26.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $4.03M | $872.6K |
| Current assets | $5.20M | $1.10M |
| Total assets | $12.16M | $2.05M |
| Current liabilities | $6.00M | $707.9K |
| Total liabilities | $7.48M | $2.23M |
| Shareholders' equity | $4.69M | -$177.4K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -$2.56M | -$1.36M |
| Investing cash flow | -$153.0K | -$99.5K |
| Financing cash flow | $6.92M | $1.15M |
| Stock-based compensation | $419.2K | $352.8K |
| Depreciation and amortization | $52.7K | $47.5K |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Research and development | $605.2K | $475.1K | $109.4K | $34.9K | $158.7K | $62.7K | $9.3K | $9.8K | $153.3K |
| Selling, general and admin | $1.38M | $1.15M | $1.14M | $2.16M | $1.75M | $1.30M | $375.7K | $319.2K | $519.7K |
| Operating income | -$1.98M | -$1.63M | -$1.25M | -$2.19M | -$1.91M | -$1.37M | -$385.0K | -$329.0K | -$673.0K |
| Interest expense | $341.2K | - | - | - | - | - | - | - | - |
| Net income | -$6.23M | -$5.85M | -$971.0K | $279.1K | -$1.90M | -$1.24M | -$328.5K | -$323.1K | -$666.4K |
| EPS, basic | -$0.21 | -$0.20 | -$0.03 | $0.01 | -$0.07 | -$0.05 | -$0.01 | - | -$0.03 |
| EPS, diluted | -$0.21 | -$0.20 | -$0.03 | $0.01 | -$0.07 | -$0.05 | -$0.01 | - | -$0.03 |
| Diluted shares | 30.1M | 29.8M | 29.5M | - | 28.0M | 27.5M | 27.0M | - | 26.6M |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $9.43M | $9.95M | $11.01M | $4.03M | $3.11M | $3.19M | $1.57M | $872.6K | $498.3K |
| Current assets | $11.08M | $10.43M | $11.45M | $5.20M | $3.29M | - | - | $1.10M | - |
| Total assets | $16.35M | $16.96M | $18.64M | $12.16M | $4.30M | - | - | $2.05M | - |
| Current liabilities | $3.48M | $8.76M | $5.13M | $6.00M | $2.31M | - | - | $707.9K | - |
| Short-term debt | $444.2K | - | - | - | - | - | - | - | - |
| Long-term debt | $5.74M | $6.06M | $5.94M | - | - | - | - | - | - |
| Total debt | $6.19M | $6.06M | $5.94M | - | - | - | - | - | - |
| Total liabilities | $10.66M | $16.27M | $12.53M | $7.48M | $3.79M | - | - | $2.23M | - |
| Shareholders' equity | $5.69M | $686.9K | $6.12M | $4.69M | $504.0K | $1.77M | $818.7K | -$177.4K | -$414.3K |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.55M | -$923.4K | -$1.63M | -$1.18M | -$588.6K | -$500.0K | -$298.1K | -$430.5K | - |
| Investing cash flow | -$16.1K | -$5.8K | -$12.2K | -$31.4K | -$89.8K | - | - | -$7.8K | - |
| Financing cash flow | $1.64M | $1 | $7.79M | $3.18M | $594.6K | $2.15M | $998.1K | $522.2K | - |
| Stock-based compensation | $713.2K | $419.2K | $280.8K | $256.4K | $39.1K | $47.2K | $76.6K | $37.8K | - |
Key ratios
Source: XBRL data Turn Therapeutics Inc. files with the SEC, latest filing dated Nov 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
TTRX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| TTRX | - | - | -$12.77M | - | $302.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
TTRX FAQ
5 questionsIs TTRX profitable?
No. Turn Therapeutics Inc. reported a net loss of $12.77M for the twelve months ended Sep 30, 2026.How much cash and debt does TTRX have?
Turn Therapeutics Inc. reported $9.43M in cash and cash equivalents and $6.19M of debt on its most recent balance sheet in SEC filings.What is TTRX earnings per share?
Diluted earnings per share were -$0.43 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did TTRX last report financial results?
The latest statements here come from Turn Therapeutics Inc.'s 10-Q filed on Nov 9, 2026, covering the period ended Sep 30, 2026.Where does this TTRX financial data come from?
Quantisnow builds these statements from the structured XBRL data Turn Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.